Redefining Dermatology Through Peptide-Drug Conjugates

Unlocking safer, more effective, consumer-friendly treatments for hair loss and inflammatory skin therapies.

Existing treatments for conditions like hair loss and inflammatory skin disorders face significant challenges:

Limited Efficacy

Many active ingredients do not penetrate deeply enough into the skin or scalp to achieve their full therapeutic effect.

Formulation Barriers

Common solutions rely on ethanol-based systems that can cause irritation, instability, or compliance issues.

Safety Concerns

Some treatments risk systemic exposure or side effects, limiting long-term use and consumer acceptance.

Our Solution

Absotride™ conjugates improve delivery, penetration, and bioavailability of dermatology actives while maintaining an excellent safety profile.

Key Advantages

Clinically relevant efficacy – Absotride conjugates show 35–42% inhibition vs. 28–65% with finasteride.
Formulation flexibility – zero-ethanol, high-solubility systems compatible with topical formats.
Safety-first design – no irritation observed and no blood exposure over 24 hours.

Potential Applications

Hair Loss Therapy – safer, more effective alternatives to conventional finasteride-based products.
Inflammatory Skin Disorders – improved delivery of actives for localized treatment.
Novel Topical Combinations – enabling next-generation peptide-drug formulations.

Actives Enabled by Absotride

Hair Regrowth & Scalp Health: Finasteride, Minoxidil, and emerging topical actives
Repair & Regeneration: enhanced efficacy of growth factors, peptides, and novel biologics to support skin healing and renewal

With Absotride, brands and researchers can deliver safer, more effective treatments in consumer-friendly topical formats—without relying on harsh enhancers or irritating solvents.